What is claimed is:

1. A fusion protein comprising an epidermal growth factor receptor variant III (EGFRvIII) polypeptide fused to a mesothelin polypeptide, wherein said fusion protein polypeptide comprises the amino acid sequence of SEQ ID NO: 8.

2. The fusion protein of claim 1, wherein said fusion protein is expressed by a bacterium.

3. The fusion protein of claim 2, wherein the bacterium is *Listeria monocytogenes*.

4. A nucleic acid molecule encoding the fusion protein of claim 1.

5. The nucleic acid molecule of claim 4, said nucleic acid molecule being part of an expression cassette.

6. A host cell comprising the nucleic acid molecule of claim 5.

7. The host cell of claim 6, wherein the *Listeria monocytogenes* is a *Listeria monocytogenes ΔactA/ΔinlB* mutant.

8. A vector comprising the nucleic acid molecule of claim 5.

9. A vaccine comprising the host cell of claim 6 and a pharmaceutically acceptable excipient.

10. A composition for eliciting an immune response in a subject comprising a host cell, wherein the host cell comprises a nucleic acid molecule encoding a polypeptide of SEQ ID NO: 8.

11. The composition of claim 10, wherein the host cell is a *Listeria monocytogenes ΔactA/ΔinlB* mutant.

12. A method of increasing expression of a mesothelin polypeptide comprising,
expressing in a host cell a nucleic acid molecule encoding a polypeptide comprising the sequence of SEQ ID NO: 8.

13. The composition of Claim 10 for treating cancer in a subject in need thereof.

14. The composition of claim 13, wherein the cancer is a mesothelin-expressing cancer, an EGFRvIII-expressing cancer, or both.

15. The composition of claim 13, wherein the cancer has a high level of mesothelin expression.

16. The composition of claim 13, wherein the cancer is lung cancer.

17. The composition of claim 16, wherein the lung cancer is non-small cell lung cancer (NSCLC) adenocarcinoma, NSCLC squamous cell carcinoma, large cell carcinoma, or any combination thereof.

18. The composition of claim 16, wherein the lung cancer is advanced NSCLC adenocarcinoma or metastatic NSCLC adenocarcinoma.

19. The fusion protein of claim 2, wherein the bacterium is a live-attenuated *Listeria monocytogenes*.

20. The host cell of claim 6, wherein the bacterium is a live-attenuated *Listeria monocytogenes*.

21. The composition of claim 10, wherein the bacterium is a live-attenuated *Listeria monocytogenes*.

22. A host cell comprising the nucleic acid molecule of Claim 4, wherein the host cell is a bacterium.

23. The host cell of claim 22, wherein the bacterium is a live-attenuated *Listeria monocytogenes*.